View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Jun. 30, 2017
Document and Entity Information
Entity Registrant Name	YIELD10 BIOSCIENCE, INC.
Entity Central Index Key	0001121702
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding	28,402,471
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float		$ 7,869,303

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 14,487	$ 7,309
Accounts receivable	54	66
Due from related parties	0	1
Unbilled receivables	65	121
Prepaid expenses and other current assets	311	363
Total current assets	14,917	7,860
Restricted cash	317	432
Property and equipment, net	1,539	1,739
Deferred equity financing costs	0	622
Other assets	109	95
Total assets	16,882	10,748
Current Liabilities:
Accounts payable	76	56
Accrued expenses	2,299	2,702
Total current liabilities	2,375	2,758
Lease incentive obligation, net of current portion	1,005	1,132
Contract termination obligation, net of current portion (Note 13)	0	489
Total liabilities	3,380	4,379
Commitments and contingencies (Note 6)
Stockholders' Equity:
Series A Convertible Preferred Stock ($0.01 par value per share); 5,000,000 authorized at December 31, 2017 and 2016, respectively; 1,826 and zero shares issued and outstanding at December 31, 2017 and 2016, respectively	818	0
Common stock ($0.01 par value per share); 40,000,000 shares and 250,000,000 shares authorized at December 31, 2017 and 2016, respectively; 9,089,159 and 2,834,244 shares issued and outstanding at December 31, 2017 and 2016, respectively	91	28
Additional paid-in capital	355,431	339,782
Accumulated other comprehensive loss	(85)	(84)
Accumulated deficit	(342,753)	(333,357)
Total stockholders' equity	13,502	6,369
Total liabilities and stockholders' equity	$ 16,882	$ 10,748

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,826	0
Preferred stock, shares outstanding	1,826	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	40,000,000	250,000,000
Common stock, shares issued	9,089,159	2,834,244
Common stock, shares outstanding	9,089,159	2,834,244

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Grant revenue	$ 944,000	$ 1,159,000
Total revenue	944,000	1,159,000
Expenses:
Research and development	4,597,000	5,670,000
General and administrative	5,630,000	5,737,000
Total expenses	10,227,000	11,407,000
Loss from continuing operations	(9,283,000)	(10,248,000)
Other income (expense), net	(113,000)	(38,000)
Net loss from continuing operations before income tax benefit	(9,396,000)	(10,286,000)
Income tax benefit	0	1,097,000
Net loss from continuing operations	(9,396,000)	(9,189,000)
Discontinued operations
Income from discontinued operations	0	2,682,000
Income tax provision	0	(1,097,000)
Total net income from discontinued operations	0	1,585,000
Net loss	(9,396,000)	(7,604,000)
Loss attributable to common shareholders and loss per common share:
Net loss	(9,396,000)	(7,604,000)
Deemed dividend on Series A Convertible Preferred Stock issuance	(1,427,000)	0
Net loss applicable to common shareholders	$ (10,823,000)	$ (7,604,000)
Basic and Diluted net loss per share:
Net loss from continuing operations (in dollars per share)	$ (3.29)	$ (3.30)
Net loss from discontinued operations (in dollars per share)	0.00	0.57
Net loss per share (in dollars per share)	$ (3.29)	$ (2.73)
Number of shares used in per share calculations:
Basic & Diluted (in shares)	3,288,618	2,781,185

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (9,396)	$ (7,604)
Other comprehensive income (loss):
Change in foreign currency translation adjustment	(1)	(12)
Total other comprehensive loss	(1)	(12)
Comprehensive loss	$ (9,397)	$ (7,616)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (9,396,000)	$ (7,604,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	206,000	515,000
Expense for 401(k) company common stock match	85,000	281,000
Stock-based compensation	1,395,000	848,000
Inventory impairment	0	199,000
Gain on sale of discontinued operation and property and equipment	0	(9,833,000)
Non-cash restructuring expense paid through stock and equipment	0	196,000
Changes in operating assets and liabilities:
Accounts receivable	12,000	172,000
Due from related parties	1,000	145,000
Unbilled receivables	56,000	29,000
Inventory	0	180,000
Prepaid expenses and other assets	660,000	1,302,000
Accounts payable	17,000	(51,000)
Accrued expenses	(622,000)	(845,000)
Contract termination obligation and other long-term liabilities	(616,000)	339,000
Deferred revenue	0	(277,000)
Net cash used in operating activities	(8,202,000)	(14,404,000)
Cash flows from investing activities
Purchase of property and equipment	(6,000)	(752,000)
Proceeds from sale of discontinued operation and property and equipment	0	10,317,000
Change in restricted cash	115,000	187,000
Net cash provided by investing activities	109,000	9,752,000
Cash flows from financing activities
Proceeds from private placement offering, net of issuance costs	1,966,000	0
Proceeds from public stock offerings, net of issuance costs	13,318,000	0
Net cash provided by (used in) financing activities	15,272,000	(296,000)
Effect of exchange rate changes on cash and cash equivalents	(1,000)	(12,000)
Net increase (decrease) in cash and cash equivalents	7,178,000	(4,960,000)
Cash and cash equivalents at beginning of period	7,309,000	12,269,000
Cash and cash equivalents at end of period	14,487,000	7,309,000
Interest paid	116	45
Supplemental Disclosure of Non-cash Information:
Stock offering costs remaining in accounts payable and accrued expenses	221,000	0
Deemed dividend related to Series A Convertible Preferred Stock beneficial conversion feature	1,427,000	0
Lease incentive paid by lessor	0	1,332,000
Transfer of equipment to settle contractual liability	0	111,000
Issuance of common stock to settle contractual liability	$ 0	$ 85,000

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated other Comprehensive Income (loss)	Accumulated Deficit	Series B Preferred Stock Preferred Stock	Aspire	Aspire Common Stock	Aspire Additional Paid-In Capital	Restricted Stock Units (RSUs)	Restricted Stock Units (RSUs) Common Stock	Restricted Stock Units (RSUs) Additional Paid-In Capital
Balance at Dec. 31, 2015	$ 13,028	$ 27	$ 338,826	$ (72)	$ (325,753)	$ 0
Balance (in shares) at Dec. 31, 2015		2,733,144				0
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	848		848
Issuance of common stock for 401k match	$ 320		320
Issuance of common stock for 401k match (in shares)	31,912	31,912
Issuance of stock in connection with private placement, net of offering costs										$ (296)	$ 1	$ (297)
Issuance of stock in connection with private placement, net of offering costs (in shares)											41,688
Issuance of common stock, preferred stock and warrants in connection with public offering, net of offering costs of $1,392	$ 85		85
Issuance of common stock upon conversion of preferred stock (in shares)		(27,500)
Effect of foreign currency translation	(12)			(12)
Net loss	(7,604)				(7,604)
Balance at Dec. 31, 2016	$ 6,369	$ 28	339,782	(84)	(333,357)	$ 0
Balance (in shares) at Dec. 31, 2016	2,834,244	2,834,244				0
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	$ 1,395		1,395
Issuance of common stock for 401k match	$ 84		84
Issuance of common stock for 401k match (in shares)	22,493	22,493
Issuance of stock in connection with private placement, net of offering costs	$ 13,097	$ 47	11,264			$ 1,786	$ 1,966	$ 5	$ 1,961	$ (12)	$ 1	$ (13)
Issuance of stock in connection with private placement, net of offering costs (in shares)		4,667,000				3,987,000		570,784			34,193
Adjustment To Additional Paid In Capital, Beneficial Conversion Feature Of Convertible Preferred Stock			1,427			$ (1,427)
Deemed Dividends To Convertible Preferred Stockholders			(1,427)			1,427
Issuance of common stock, preferred stock and warrants in connection with public offering, net of offering costs of $1,392		$ 10	958			$ (968)
Issuance of common stock upon conversion of preferred stock (in shares)		(960,445)				2,161,000
Effect of foreign currency translation	(1)			(1)
Net loss	(9,396)				(9,396)
Balance at Dec. 31, 2017	$ 13,502	$ 91	$ 355,431	$ (85)	$ (342,753)	$ 818
Balance (in shares) at Dec. 31, 2017	9,089,159	9,089,159.000				1,826,000

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Shares withheld for employee taxes	2,700	18,900
Registered Direct Offering
Issuance of common stock upon private offering, offering costs		$ 317
Public Offering
Issuance of common stock upon private offering, offering costs		$ 1,392

Nature of Business and Basis of Presentation	12 Months Ended
Nature of Business and Basis of Presentation	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Nature of Business and Basis of Presentation Yield10 Bioscience, Inc. ("Yield10 Bioscience," "Yield10," or the "Company") was founded as Metabolix, Inc. in 1992 and changed its name in January 2017. Yield10 Bioscience is an agricultural bioscience company focusing on the development of new technologies to enable step-change increases in crop yield to enhance global food security. Yield10 is using two proprietary advanced biotechnology trait gene discovery platforms to improve fundamental crop yield through enhanced photosynthetic carbon capture and increased carbon utilization efficiency to increase seed yield. These platforms are based on the principle that plants which capture and utilize carbon more efficiently will enable more robust crops capable of increased seed yield. Yield10 is working to translate and demonstrate the commercial value of novel yield trait genes it has identified in major crops and to identify additional genome editing targets for improved crop performance in several key food and feed crops, including canola, soybean, rice and corn. Yield10 Bioscience is headquartered in Woburn, Massachusetts and has an additional agricultural science facility with greenhouses located in Saskatoon, Saskatchewan, Canada. The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of 2012, when the Company recognized $38,885 of deferred revenue from a terminated joint venture, the Company has recorded losses since its initial founding, including its fiscal year ending December 31, 2017. During 2016, the Company completed a strategic restructuring under which Yield10 Bioscience became its core business. In connection with the restructuring, the Company discontinued its pilot biopolymer production and other biopolymer operations, sold substantially all of its biopolymer assets to CJ CheilJedang Corporation ("CJ") and reduced staffing levels to approximately twenty full-time employees in order to focus on crop science activities and significantly reduce the Company's cash burn rate used in operations. During 2016, the Company recorded restructuring charges of $3,513 and as of December 31, 2017, restructuring obligations of $489 remain outstanding with payment due dates through May 2018. As of December 31, 2017, the Company held unrestricted cash and cash equivalents of $14,487. The Company follows the guidance of ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40) in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. Based on its cash forecast, management has determined that the Company's present capital resources are sufficient to fund its planned operations for at least the next twelve month period from the date that these financial statements are issued. If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986 due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Principles of Consolidation

The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc. During 2016, the Company completed the sale of its biopolymer intellectual property and certain equipment and inventory to an affiliate of CJ in a transaction that met the requirements for discontinued operations reporting in accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The consolidated financial statements for the year ended December 31, 2016 have been presented to reflect the Company's biopolymer operation as a discontinued operation.

Reverse Stock Split

On May 26, 2017, the Company effected a 1-for-10 reverse stock split of its common stock. Unless otherwise indicated, all share amounts, per share data, share prices, and conversion rates set forth in these notes and the accompanying financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

Investments

The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. All other investments are classified as long-term. The Company held no short or long-term investments at December 31, 2017 or December 31, 2016.

Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.

Restricted Cash

The Company had restricted cash in the amount of $317 and $432 at December 31, 2017, and December 31, 2016, respectively. At December 31, 2017, restricted cash consists primarily of funds held in connection with the lease agreement for the Company's Woburn, Massachusetts facility.

Deferred Equity Financing Costs

The Company entered into a common stock purchase agreement in 2015 with Aspire Capital Fund, LLC, (Aspire) under which Aspire committed to purchase up to an aggregate of $20,000 of the Company's common stock over a 30-month period. Offering costs incurred to establish this agreement were recorded as deferred equity financing costs. These costs were expected be charged to additional paid-in-capital as shares were issued under the agreement. Aspire purchase transactions would have utilized pricing formulas that qualified them as variable rate transactions, as defined in the securities purchase agreement entered into in connection with the Company's securities offering completed in July 2017. Because variable rate transactions are prohibited by the securities agreement, the Aspire facility was no longer available to the Company as a source of capital. Therefore, the deferred equity offering costs can no longer be offset against future common stock issuances to Aspire. As such, the Company recognized the full deferral of $622 during the year ended December 31, 2017 within general and administrative expense.

Foreign Currency Translation

Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net income (loss) and certain changes in stockholders' equity that are excluded from net income (loss). The Company includes unrealized gains and losses on marketable securities and foreign currency translation adjustments in other comprehensive income (loss).

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer. At December 31, 2017, the Company's cash equivalents were invested solely in a money market fund.

The Company's receivables related to government grants are believed to have a low risk of default. At December 31, 2017, the Company's accounts and unbilled receivables of $119, include $104, or 87%, that are amounts due from research grants with the U.S. government under which the Company serves as either the primary contractor or as a subcontractor. At December 31, 2016, the Company's accounts and unbilled receivables of $187 are all from government research grants.

Fair Value Measurements

The carrying amounts of the Company's financial instruments as of December 31, 2017 and 2016, which include cash equivalents, accounts receivable, unbilled receivables, receivables due from related parties, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 3 for further discussion on fair value measurements.

Segment Information

The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results. As of December 31, 2017 and December 31, 2016, less than 10% of the Company's combined total assets were located outside of the United States. In addition, the reported net income (loss) outside of the United States was less than 10% of the combined net income (loss) of the consolidated Company.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Repairs and maintenance are charged to operations as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and Fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

The Company records incentive payments received from its landlords as a lease incentive obligation and amortizes these amounts as reductions to lease expense over the lease term.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.

Grant Revenue

The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor. These grants are considered an ongoing major and central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December 31, 2017 and December 31, 2016. Funds received from government grants in advance of work being performed are recorded as deferred revenue until earned.

Research and Development

All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, product trials, facility related expenses, depreciation, and stock-based compensation. Costs related to revenue-producing contracts and government grants are recorded as research and development expenses.

General and Administrative Expenses

The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation expenses and office related expenses incurred to support the administrative operations of the Company.

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

All share-based payments to employees, members of the Board of Directors and non-employees are recognized in the statement of operations based on their fair values. For employees and members of the Company's Board of Directors, who receive nearly all of the Company's stock awards, stock compensation expense is recognized based on the grant-date fair value of the award, adjusted for estimated forfeitures, and is recognized on a straight-line basis over the period during which the recipient is required to provide service in exchange for the award. See Note 9 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.

Basic and Diluted Net Loss per Share

Basic net income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net income available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, such as the Company's fiscal years ending December 31, 2017 and 2016, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, there is no difference in basic and dilutive loss per share. Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.

The Company follows the two-class method when computing net loss per share, when it has issued shares that meet the definition of participating securities. The two-class method determines net income per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. In periods of net loss, a participating security that does not have a contractual obligation to share in the loss is not allocated a portion of the net loss when determining loss per share under the two-class method. During December 2017, the Company completed an offering of its securities that included preferred shares meeting the definition of participating securities (See Note 8). However, due to the Company's net loss in 2017, no allocation of the net loss was allocated to the preferred shares as the holders of the preferred shares do not have a contractual obligation to fund losses and loss per share has been computed and presented based on the loss being fully assigned to the Company's weighted average outstanding common shares during the year. There were no amounts allocated to participating securities during the year ended December 31, 2016. as the Company had no outstanding securities that met the definition of participating securities.

The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units, convertible preferred stock and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the years ended December 31, 2017 and 2016, respectively, are shown below:



	Year Ended December 31,
	2017	2016
Options	622,329	89,862
Restricted stock awards	16,165	70,748
Series A Convertible Preferred Stock	30,553	—
Warrants	943,749	393,300
Total	1,612,796	553,910

In July 2016, the Board of Directors of the Company approved a strategic restructuring plan under which Yield10 Bioscience became its core business with a focus on developing new technologies for step-change improvements in crop yield to enhance global food security. In connection with this restructuring, the Company discontinued its biopolymer operations. The Company's consolidated statement of operations for the year ending December 31, 2016, included in this annual report has been prepared to present basic and diluted earnings per share from continuing and discontinued operations.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax asset to a level which, more likely than not, will be realized. See Note 10 for further discussion of income taxes. The Company had no amounts recorded for any unrecognized tax benefits as of December 31, 2017 and 2016.

The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.

Restructuring Charges

In July 2016, the Company announced a strategic restructuring under which Yield10 Bioscience became its core business and its biopolymer operations were discontinued. The Company records estimated restructuring charges for employee severance and contract termination costs as a current period expense as those costs become contractually fixed, probable and estimable. The long and short-term obligations associated with these charges is reduced or adjusted as payments are made or the Company's estimates are revised.

Recent Accounting Standards Changes

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.

In March 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. The new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. The new standard was effective for Yield10 Bioscience on January 1, 2017. The adoption of this standard did not have an impact on the Company's financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The new standard was effective for the Company on January 1, 2017. The adoption of this standard did not have an impact on our financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The Company adopted the new standard effective January 1, 2017 and the adoption did not have a material impact on the Company's financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU is the result of a joint project by the FASB and the International Accounting Standards Board ("IASB") to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards ("IFRS") that would: remove inconsistencies and weaknesses, provide a more robust framework for addressing revenue issues, improve comparability of revenue recognition practices across entities, jurisdictions, industries, and capital markets, improve disclosure requirements and resulting financial statements, and simplify the presentation of financial statements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU was effective for annual reporting periods beginning after December 15, 2016 and early adoption was not permitted. On July 9, 2015, the FASB voted to delay the effective date of the new revenue standard by one year, but to permit entities to choose to adopt the standard as of the original date. The Company will adopt the new standard effective January 1, 2018, electing to utilize the modified retrospective method of adoption. The Company evaluated the effect the new revenue standard will have on its consolidated financial statements and related disclosures and has determined that its grant revenue, which is its sole source of revenue, does not fall within the guidance of the new standard. The Company will review future sources of revenue agreements against the guidance provided by ASU No. 2014-09 to ensure that revenue is recorded appropriately.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard became effective for the Company on January 1, 2018 and is not expected to have a material impact on the Company's financial statements.

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in the Company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard became effective for Yield10 Bioscience on January 1, 2018. The Company does not expect the new guidance to have a material impact on its financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for Yield10 Bioscience on January 1, 2019. The Company is in the process of evaluating the impact of this new guidance.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for the Company on January 1, 2020. The Company is in the process of evaluating the impact of this new guidance.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. The new standard became effective for Yield10 Bioscience on January 1, 2018. The Company does not expect the new guidance to have a material impact on its financial statements.

In August 2017 the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvement to Accounting for Hedging Activities. This new standard is intended to simplify hedge accounting by better aligning how an entity's risk management activities and hedging relationships are presented in its financial statements and simplifies the application of hedge accounting guidance in certain situations. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The new standard will become effective for the Company on January 1, 2020. The Company does not expect the new guidance to have a material impact on its financial statements.

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company has certain financial assets recorded at fair value which have been classified as Level 1 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input. At December 31, 2017 and 2016, the Company did not own any Level 2 or Level 3 financial assets or liabilities and there were no transfers of financial assets or liabilities between category levels for the years then ended. The Company's assets are measured at fair value on a recurring basis. The balance of Level 1 assets as of December 31, 2017 and December 31, 2016 were $11,025 and $1,018, respectively, and for both years the assets were in a money market fund classified within cash and cash equivalents.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property and Equipment, Net

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Property and equipment consist of the following:



	Year ended December 31,
	2017			2016
Equipment	$	1,059		$	1,048
Furniture and fixtures	119			226
Leasehold improvements	1,749			1,825
Software	96			116
Total property and equipment, at cost	3,023			3,215
Less: Accumulated depreciation	(1,484		)	(1,476		)
Property and equipment, net	$	1,539		$	1,739

Depreciation expense for continuing operations for the years ended December 31, 2017 and 2016, was $206 and $177, respectively.

Accrued Expenses

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following:



	Year ended December 31,
	2017		2016
Employee compensation and benefits	$	646	$	713
Commercial manufacturing	489		939
Professional services	335		459
Other	829		591
Total accrued expenses	$	2,299	$	2,702

Included within accrued professional services at December 31, 2017 is $216 of professional fees related to the Company's securities offering that was completed in December. Included within accrued employee compensation and benefits at December 31, 2016 is $626 of employee post-employment severance associated with the Company's restructuring that was completed during 2016. See Note 13. There were no further severance accruals remaining at December 31, 2017.

Accrued commercial manufacturing expenses at December 31, 2017 and December 31, 2016, is comprised of the current portion of the Company's terminated biopolymer manufacturing contract obligation See Note 13.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Leases

The Company rents its facilities under operating leases, which expire at various dates through December 2026. Rent expense within continuing operations under operating leases for the years ended December 31, 2017 and 2016, was $954 and $1,889, respectively.

At December 31, 2017, the Company's future minimum payments required under operating leases are as follows:



Year ended December 31,	Minimum lease payment
2018	$	917
2019	855
2020	734
2021	654
2022	676
2023 and thereafter	2,832
Total	$	6,668

Lease Commitments

In 2016 the Company entered into a lease agreement, pursuant to which the Company leases approximately 29,622 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease began on June 1, 2016 and will end on November 30, 2026. The Company provided the landlord with a security deposit in the form of a letter of credit in the amount of $307. Pursuant to the lease, the Company also will pay certain taxes and operating costs associated with the premises throughout the term of the lease. During the buildout of the rented space, the landlord paid $889 for tenant improvements to the facility and an additional $444 for tenant improvements that result in increased rental payments by the Company. The current and non-current portions of the lease incentive obligations related to the landlord’s contributions toward the cost of tenant improvements are recorded within accrued expenses and long-term lease incentive obligation, respectively, in the Company's consolidated balance sheet contained herein.

On October 10, 2016, the Company entered into a sublease agreement with a subsidiary of CJ for the sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The subleased space was determined to be in excess of the Company's needs as a result of its strategic shift to Yield10 Bioscience and the related 2016 restructuring of its operations. The sublease is coterminous with the Company's master lease. CJ will pay rent and operating expenses equal to approximately one-third of the amounts payable to the landlord by the Company, as adjusted from time-to-time in accordance with the terms of the master lease. Total future minimum operating lease payments of $6,668 shown above are net of the CJ sublease payments. In October 2016, CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.

The Company also leases approximately 13,702 square feet of office and laboratory space at 650 Suffolk Street, Lowell, Massachusetts. The lease for this facility expires in May 2020, with an option to renew for one five-year period. The Company is currently working with a commercial real estate broker to locate a subtenant for this space. The Company's wholly-owned subsidiary, Metabolix Oilseeds, Inc. ("MOI"), located in Saskatoon, Saskatchewan, Canada, leases approximately 4,100 square feet of office, laboratory and greenhouse space. MOI's leases for its various leased facilities expire between July 31, 2018 and September 30, 2018.

Contractual Commitments

In connection with the wind down of its biopolymer operations, the Company ceased pilot production of biopolymer material and reached agreements with the owner-operators of its biopolymer production facilities regarding the termination of their services. The Company recorded contract termination costs related to these manufacturing agreements of $2,641 during 2016, which is included within discontinued operations in the Company's statement of operations for the year ended December 31, 2016. As of December 31, 2017, approximately $489 of the obligations remain outstanding with the last payment due by May 2018. This remaining contractual liability is included in accrued expenses within the Company's consolidated balance sheet at December 31, 2017.

Litigation

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations.

Guarantees

As of December 31, 2017 and 2016, the Company did not have significant liabilities recorded for guarantees.

The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of December 31, 2017 and December 31, 2016.

License Agreements and Related Parties	12 Months Ended
License Agreements and Related Parties	Dec. 31, 2017
Related Party Transactions [Abstract]
License Agreements and Related Parties	License Agreements and Related Parties The Company previously licensed certain technology to Tepha, Inc., ("Tepha") a related party, for use in medical applications. Dr. Sinskey, a member of Yield10's Board of Directors, serves on the board of Tepha, Dr. Peoples and Dr. Sinskey are stockholders of Tepha and Yield10 owns 648,149 shares of Tepha's Series A redeemable convertible preferred stock. During May 2016, the Company entered into an amendment to its license agreement with Tepha in which the Company received a lump sum payment of $2,000 in consideration for an early buyout of all future royalties under the agreement and the licensing of two additional production strains and related intellectual property that was fully delivered to Tepha during 2016. The Company recognized $2,272 of license and royalty revenue from Tepha for the year ended December 31, 2016. During 2016, the Company also received $11 from Tepha in connection with their purchase of certain laboratory equipment previously used in the Company's biopolymer operations. At December 31, 2016, the Company had outstanding receivables due from Tepha of $1. After 2016, the Company has had no further licensing or royalty arrangements with Tepha that would generate revenue or incur expenses. During June 2016, the Company entered into a purchase and licensing agreement with a third party in which the Company received a lump sum payment of $1,000 in consideration for the sale of certain biopolymer inventory and a non-exclusive license to certain patents owned or controlled by the Company related to biopolymers. The Company recorded license fee and royalty revenue of $850 and product sales of $150 for the year ended December 31, 2016, related to this agreement. The patents underlying these license agreements are now owned by CJ. As a consequence of this sale and the Company's discontinuation of its biopolymer operations, license fee and royalty revenue is included within income (loss) from discontinued operations within the Company's consolidated statements of operations for the year ended December 31, 2016. See Note 14.

Capital Stock

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Capital Stock

Common Stock

On December 27, 2017, the Company held a special meeting of its stockholders in which the stockholders approved an amendment to the Company's Certificate of Corporation to decrease from 250,000,000 shares to 40,000,000 shares the aggregate number of shares of common stock that are authorized to be issued. As a result of this vote, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to decrease the number of authorized shares effective on the date of the special meeting.

During December 2017, the Company closed on a public offering of its securities, receiving cash proceeds of $13,318, net of issuance costs of $1,171 that were paid as of December 31, 2017. The Company will pay remaining offering costs of $221 during its first quarter of 2018. The offering included 4,667,000 Class A Units, priced at a public offering price of $2.25 per unit, with each unit consisting of one share of common stock, a Series A five-year expiration warrant to purchase one share of common stock at an exercise price of $2.25 per share, and a Series B nine-month expiration warrant to purchase 0.5 share of common stock at an exercise price of $2.25 per share, and 3,987 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of preferred stock, having a conversion price of $2.25, Series A five-year warrants to purchase 445 shares of common stock at an exercise price of $2.25 per share, and Series B nine-month warrants to purchase 223 shares of common stock with an exercise price of $2.25 per share. The Company determined that both the preferred stock and the warrants should be recorded within stockholders' equity at December 31, 2017.

Proceeds received from the offering were allocated to the various elements of the offering based on their relative fair values. The fair value of the Common Stock is its closing market price on the December 21, 2017, the closing date of the offering. The Series A Convertible Preferred Stock was valued on an as-if-converted basis based on the underlying common stock and the Series A and Series B warrants were valued using the Black-Scholes model with the following weighted-average input at the time of issuance:


•	an expected term of 5.0 years and 0.75 years for the Series A and Series B warrants, respectively,


•	risk free rates of 2.2 percent and 1.7 percent for the Series A and Series B warrants, respectively, based on the published rates of U.S. treasury bills with similar terms, and


•	volatility of 125 percent based on the Company’s historical volatility.

After allocation of the proceeds, the effective conversion price of the Series A Convertible Preferred Stock was determined to be beneficial and, as a result, the Company immediately recorded a one-time non-cash deemed dividend of $1,427 equal to the intrinsic value of the beneficial conversion feature. The Series A Convertible Preferred Stock does not have a stated redemption date, and as a consequence, accounting guidance requires immediate recognition of a beneficial conversion feature rather than amortization of the benefit over time. The Series A Convertible Preferred Stock is considered a participating security. In accordance with applicable accounting guidance, the Company's loss of $9,396 from continuing operations has been increased by the amount of the deemed dividend resulting in a net loss attributable to common shareholders of $10,823. As of December 31, 2017, preferred shareholders have converted 2,161 of the preferred shares into 960,445 shares of common stock.

On September 12, 2017, the Company issued warrants to purchase 30,000 shares of common stock to the Company's investor relations consultant, in consideration for services rendered and to be rendered by the consultant. These warrants have an exercise price of $2.90 per share and are exercisable in whole or part at any time during the period commencing on September 12, 2017 and ending on September 11, 2024. The Company reviewed the accounting guidance for warrants and determined that the warrants should be recorded as equity within additional paid-in capital.

On July 7, 2017, the Company completed a registered direct offering of its securities. Proceeds from the transaction were approximately $1,966, net of estimated issuance costs of $317. Investors participating in the transaction purchased a total of 570,784 shares of common stock at a price of $4.00 per share and an equal number of warrants with an exercise price of $5.04 per share, exercisable beginning on the six-month anniversary of the date of issuance. The warrants expire on the sixth anniversary of the date that they become exercisable. The Company reviewed the accounting guidance for warrants and determined that the warrants should be recorded as equity within additional paid-in capital.

On May 26, 2017, the Company effected a 1-for-10 reverse stock split of its common stock. The ratio for the reverse stock split was determined by the Company's board of directors following approval by stockholders at the Company's annual meeting held on May 24, 2017. The reverse stock split reduced the number of shares of the Company's common stock outstanding at the time of the reverse stock split from approximately 28.7 million shares to approximately 2.9 million shares. Proportional adjustments were made to the Company's outstanding stock options and restricted stock units and to the number of shares issued and issuable under the Company's equity compensation plans. The number of authorized shares of the Company's common stock at that time remained at 250,000,000 shares.

In connection with the 2016 wind down of biopolymer operations, the Company ceased pilot production of biopolymer material at its third-party biopolymer pilot production facilities. In September 2016, the Company entered into an early termination agreement with the owner-operator of one of the biopolymer production facilities. As part of the consideration for the early termination, the Company issued 27,500 unregistered shares of Yield10 Bioscience common stock (see Note 13).

In October 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (Aspire) under which Aspire committed to purchase, at the Company's direction, up to an aggregate of $20,000 of shares of Company common stock over a 30 month period. Aspire purchase transactions would have utilized pricing formulas that qualify them as variable rate transactions, as defined in the securities purchase agreement entered into in connection with the Company's securities offering completed in July 2017. Because variable rate transactions are prohibited by the securities agreement entered into in conjunction with the Company's July 7, 2017 offering, the Aspire facility is no longer available to the Company as a source of capital. During the year ended December 31, 2017, the Company wrote off its deferred equity offering costs of $622 related to the Aspire agreement since the Company no longer intends to pursue transactions under this agreement. Expense related to this write off of deferred equity offering costs are included within general and administrative expense within the Company's condensed consolidated statements of operations for the year ended December 31, 2017, included herein.

Preferred Stock

The Company's certificate of incorporation, as amended and restated, authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.

As discussed above, during December 2017 the Company closed on a public offering of its securities that included issuance of 3,987 shares of Series A Convertible Preferred Stock. Each preferred share is convertible, at the holder's option, into 445 shares of common stock at a conversion price of $2.25 per share, subject to adjustments as a result of stock dividends and stock splits. Holders of the Series A Convertible Preferred Stock are entitled to certain purchase rights that provide them with the opportunity to participate in subsequent rights offerings on the same terms that holders of Common Stock would receive as if the preferred stock were fully converted into common shares. If the Company enters into certain Fundamental Transactions, as defined in the offering documents, including mergers, asset sales or other business combinations, preferred shareholders are entitled to participate and receive value equal to common shareholders, on a converted basis. The Series A Convertible Preferred Stock has no maturity date and holders of the Series A Convertible Preferred Stock have no voting rights, with the exception that an affirmative vote of a majority of the holders of any remaining outstanding preferred shares is required in order to change the preferences or rights of the preferred shares. The Series A Preferred Stock is not redeemable by the Company and preferred shareholders are entitled to receive dividends on the preferred shares equal to and in the same form as dividends paid on shares of Common Stock. Upon liquidation, dissolution or winding-up of the Company, holders of the Series A Convertible Preferred Stock are entitled to receive out of the assets, whether capital or surplus, the same amount that holders of common stock would receive as if the preferred stock were fully converted to common shares. The Series A Preferred Stock is convertible, at the Company's option, if during any 30 consecutive trading days the closing market price of the Company's Common Stock exceeds $6.75 per share, subject to certain adjustments for stock splits, recapitalizations and stock dividends, and the daily dollar trading volume exceeds $175.

The Company determined the Series A Convertible Preferred Stock should be classified as equity as it is not mandatorily redeemable, there are no unconditional obligations requiring the Company to settle in a variable number of common shares or settle through the transfer of assets and the monetary value of the preferred shares is fixed. As of December 31, 2017, 2,161 preferred shares had been converted to 960,445 shares of common stock, leaving a remaining balance of 1,826 shares of the Series A Convertible Preferred Stock outstanding as of that date. Through March 5, 2018, an additional 1,718 shares of the Company's Series A Convertible Preferred Stock were converted into 763,556 shares of common stock. Once converted, the shares of converted Series A Convertible Preferred Stock are restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors. At December 31, 2016 there were no shares of preferred stock issued or outstanding.

Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2017:



Issuance	Number of Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
June 2015 Private Placement	393,300	$	39.80	June 15, 2019
July 2017 Registered Direct Offering	570,784	$	5.04	January 7, 2024
December 2017 Public Offering - Series A	6,439,000	$	2.25	December 21, 2022
December 2017 Public Offering - Series B	3,219,502	$	2.25	September 21, 2018
Consultant	30,000	$	2.90	September 11, 2024
Total	10,652,586

Reserved Shares

The following common stock shares were reserved for future issuance upon exercise of stock options, release of Restricted Stock Units ("RSUs"), conversion of outstanding Series A Convertible Preferred Stock and conversion of outstanding warrants:



	December 31, 2017	December 31, 2016
Stock Options	702,033	605,077
RSUs	14,367	21,735
Series A Convertible Preferred Stock	811,555	—
Warrants	10,652,586	393,300
Total number of common shares reserved for future issuance	12,180,541	1,020,112

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

The Company adopted a stock plan in 2006 (the "2006 Plan"), which provided for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. In October 2014, the 2006 Plan was terminated and the Company adopted a new plan (the "2014 Plan"). No further grants or awards were subsequently made under the 2006 Plan. A total of 146,724 options were awarded from the 2006 Plan and as of December 31, 2017, 24,984 of these options remain outstanding and eligible for future exercise.

The 2014 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. A total of 663,104 options have been awarded from the 2014 Plan and as of December 31, 2017, 657,882 of these options remain outstanding and eligible for future exercise. A total of 144,541 restricted stock awards have been awarded from the 2014 Plan and as of December 31, 2017, 14,367 of these restricted stock awards are unvested and outstanding.

Expense Information for Employee Stock Awards

The Company recognized stock-based compensation expense, related to employee stock awards, including awards to non-employees and members of the Board of Directors, of $1,395 and $848 for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, there was approximately $986 of stock-based compensation expense related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of 0.81 years.

Stock Options

Options granted under the 2006 Plan and the 2014 Plan (the "Plans") generally vest ratably over periods of one to four years from the date of hire for new employees, or date of award for existing employees, or date of commencement of services with the Company for non-employees, and generally expire ten years from the date of issuance. The Company's policy is to issue new shares upon the exercise of stock options.

On October 26, 2016, the Company's Compensation Committee granted stock options for a total of 456,000 shares to employees who remained with the Company after the Company's strategic restructuring was completed. Each option has an exercise price per share equal to the fair market value of the Company's common stock on the date of grant, vests in 4 equal semi-annual installments at a rate of 25 percent per installment over 2 years, and has a term of ten years from the date of grant.

On November 4, 2016, the Company's former chief executive officer ("CEO"), was granted stock options for 75,000 shares upon the execution of separation and release agreements relating to the termination of his employment with the Company. These options have an exercise price per share equal to the fair market value of the Company's common stock on the date of grant, were fully vested on the date of grant, became exercisable on the effective date of the release agreement, and will remain exercisable through December 19, 2023. The Company recognized the full fair value of this award as stock compensation expense in its fiscal year ended December 31, 2016.

In December 2013, the Company's Board of Directors granted a non-qualified stock option award for the purchase of 19,167 shares of common stock to its former CEO in connection with his agreement to serve as a member of the Company's Board and to accept employment as its President and Chief Executive Officer. Upon execution of his separation agreement on November 4, 2016, the 14,375 remaining unvested stock options under this award became fully vested. The Company accounted for this vesting as an award modification and recorded the new fair value of the remaining options as expense during the Company's fiscal year ended December 31, 2016.

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:



	Number of Shares		Weighted Average Exercise Price	Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2016	605,077		$34.49
Granted	122,998		2.75
Exercised	—		—
Forfeited	(2,534	)	5.55
Expired	(23,508	)	417.30
Balance at December 31, 2017	702,033		16.21	8.40	$—
Vested and expected to vest at December 31, 2017	702,033		16.21	8.38	—
Exercisable at December 31, 2017	436,522		22.87	8.12	—

The weighted average grant date fair value per share of options granted during fiscal years 2017 and 2016, was $2.10, and $3.06, respectively. No options were exercised during 2017 and 2016, and therefore the intrinsic value for exercised options during the two years was not applicable. The weighted average remaining contractual term for options outstanding as of December 31, 2017 was 8.4 years.

For the years ended December 31, 2017, and 2016, the Company determined the fair value of stock options using the Black-Scholes option pricing model with the following assumptions for option grants, respectively:



	Year Ended December 31,
	2017	2016
Expected dividend yield	—	—
Risk-free rate	1.79% - 2.20%	1.24% - 2.04%
Expected option term (in years)	5.3-5.5	5.4-5.7
Volatility	97% - 104%	93% - 96%

The Company determined its volatility assumption based on actual market price fluctuations experienced during its trading history. The risk-free interest rate used for each grant is equal to the U.S. Treasury yield curve in effect at the time of grant for instruments with a term similar to the expected life of the related option. The expected term of the options is based upon evaluation of historical and expected future exercise behavior.

The stock price volatility and expected terms utilized in the calculation involve management's best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. The accounting standard for stock-based compensation requires that the Company recognize compensation expense for only the portion of options that vest. The Company recognizes stock option forfeitures resulting from award terminations in the period in which the occurs.

Restricted Stock Units

The Company records stock compensation expense for RSUs on a straight line basis over their vesting period based on each RSU's award date market value. During the year ended December 31, 2017, the Company awarded a total of 25,337 RSUs to its non-employee directors in lieu of cash compensation for their services. These RSUs vested upon issuance resulting in immediate recognition of stock compensation expense for the fair value of the awards.

The Company initiated use of RSUs as a broad-based form of long-term compensation incentive for its officers, directors and employees during 2015. During 2015, the Company awarded 20,397 RSUs under the 2014 Plan to members of senior management pursuant to elections previously made by the senior managers to convert a portion of their 2014 performance bonuses from cash to equity. These RSUs vested one year later on April 1, 2016. During the year ended December 31, 2015, the Company also awarded a total of 90,682 additional long-term incentive RSUs to senior management and employees. These RSUs vest in 4 equal annual installments beginning one year after the date of grant, subject to service conditions. Also during 2015, the Company awarded 8,125 RSUs to its non-employee directors that vested on May 28, 2016.

Upon execution of the separation agreement with our former CEO on November 4, 2016, the Company accelerated the vesting of 15,125 previously outstanding RSUs awarded to him in 2015. The Company recorded stock compensation expense for the fair value of these RSUs during its fiscal year ended December 31, 2016, as a result of the accelerated vesting. The accelerated vesting of the RSUs and existing stock options previously discussed was provided pursuant to the terms of the separation agreement in lieu of any cash severance and a 2016 cash bonus payable under the CEO's previous employment agreement.

The Company will pay minimum required income tax withholding associated with RSUs for its employees. As the RSUs vest, the Company will withhold a number of shares with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date. During the years ended December 31, 2017 and December 31, 2016, the Company withheld vested shares with a fair value of $12 and $296 to pay for minimum tax withholding associated with RSU vesting.

A summary of RSU activity for the year ended December 31, 2017 is as follows:



	Number of RSUs			Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2016	21,735
Awarded	25,337
Released	(32,542		)
Forfeited	(163		)
Outstanding at December 31, 2017	14,367			0.75

Weighted average remaining recognition period (years)	1.25
Weighted average grant date fair value of RSUs granted during the year ended December 31, 2017	$	4.63

Expense Information for Non-employee Stock Awards

During the year ended December 31, 2016, the Company granted stock options to purchase 5,500 shares of common stock to non-employee members of the Company's scientific advisory board. The compensation expense related to these options is to be recognized over a period of 2 years. The granted options vest 50% annually and such vesting is contingent upon future services provided by the advisors to the Company. No options were awarded for the year ended December 31, 2017 to non-employees. Options remaining unvested for non-employees are subject to remeasurement each reporting period prior to their vesting in full. Since the fair market value of the options issued to non-employees is subject to change in the future, the compensation expense recognized each year may not be indicative of future stock-based compensation charges.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Tax Cuts and Jobs Act

In December 2017, the Tax Cuts and Jobs Act, or the Tax Act ("TCJA"), was signed into law. Among other things, the Tax Act permanently lowers the corporate federal income tax rate to 21% from the existing maximum rate of 35%, effective for tax years including or commencing January 1, 2018. As a result of the reduction of the corporate federal income tax rate to 21%, U.S. GAAP requires companies to revalue their deferred tax assets and deferred tax liabilities as of the date of enactment, with the resulting tax effects accounted for in the reporting period of enactment. This revaluation resulted in a provision of $10,609 to income tax expense in continuing operations and a corresponding reduction the Company's valuation allowance. There is no impact, therefore, to the Company's income statement for the year ended December 31, 2017 as a result of the reduction in federal income tax rates. The Company's preliminary estimate of the TCJA and the remeasurement of its deferred tax assets and liabilities is subject to the finalization of management's analysis related to certain matters, such as developing interpretations of the provisions of the TCJA, changes to certain estimates and the filing of its tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting TCJA may require further adjustments and changes to the Company's estimates. The final determination of the TCJA and the remeasurement of the Company's deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the TCJA.

Income Taxes and Deferred Tax Assets and Liabilities

The components of loss from continuing operations before provision for income taxes consist of the following:



	Year Ended December 31,
	2017			2016
Domestic	$	(9,523	)	$	(10,318	)
Foreign	126			48
Loss before taxes	$	(9,397	)	$	(10,270	)

Significant components of the Company's net deferred tax assets are as follows:



	Year Ended December 31,
	2017			2016
Deferred Tax Assets:
Net operating loss carryforward	$	20,490		$	25,182
Capitalization of research and development expense	1,606			2,634
Credit carryforwards	2,493			2,048
Depreciation	990			1,505
Stock compensation	1,035			2,414
Other temporary differences	794			1,202
Total deferred tax assets.	27,408			34,985
Valuation allowance	(27,408		)	(34,985		)
Net deferred tax assets	—			—
Deferred Tax Liabilities:
Other temporary differences	—			—
Net deferred taxes	$	—		$	—

The reported amount of income tax expense for the years differs from the amount that would result from applying domestic federal statutory tax rates to pretax losses primarily because of changes in valuation allowance and due to a reduction in deferred tax assets as a result of the rate reduction under TCJA.

Tax Rate

The items accounting for the difference between the income tax benefit computed at the federal statutory rate of 34% and the provision for income taxes were as follows:



	Year Ended December 31,
	2017		2016
Federal income tax at statutory federal rate	34.0	%	34.0	%
State taxes	4.9	%	5.0	%
Permanent differences	(2.3	)%	(1.9	)%
Tax credits	3.7	%	7.4	%
Federal rate change under tax reform	(112.9	)%	0.0	%
State rate change on deferred balances	0.1	%	(0.6	)%
Impact of ownership change	0.0	%	(6.1	)%
Stock compensation	(12.7	)%	(22.9	)%
Other	1.2	%	(0.5	)%
Change in valuation allowance	84.0	%	(3.7	)%
Total	0.0	%	10.7	%

Tax Attributes

At December 31, 2017, the Company had net operating loss carryforwards (NOLs) for federal, state and international income tax purposes of approximately $72,941, $68,028 and $2,702, respectively. The Company's existing federal and state net operating loss carryforwards will begin to expire on various dates through 2037. The Company also had available research and development and investment tax credits for federal and state income tax purposes of approximately $1,282 and $787, respectively. These federal and state research and development credits will begin to expire on various dates through 2037. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets.

Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed an evaluation of its ownership changes through December 31, 2015 and determined that an ownership change occurred on August 22, 2014 in connection with an equity offering. As a consequence of this ownership change, the Company's NOLs, tax credit carryforwards and other tax deductions allocable to the tax periods preceding the ownership change became subject to limitation under Section 382. The Company has reduced its associated deferred tax assets accordingly. The Company has not yet completed an evaluation of ownership changes for the years 2016 and 2017. To the extent an ownership change occurs in the future, the net operating loss, credit carryforwards and other deferred tax assets may be subject to further limitations.

Other

The tax years 2014 through 2017 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S. The statute of limitations for net operating losses utilized in future years will remain open beginning in the year of utilization.

The Company's policy is to record estimated interest and penalties related to uncertain tax positions as income tax expense. As of December 31, 2017 and 2016, the Company had no accrued interest or penalties recorded related to uncertain tax positions.

For the year ended December 31, 2016, the Company recognized tax expense of $1,097 as a result of net income recorded for discontinued operations. This tax expense is offset in consolidation by a tax benefit of $1,097 as a result of the Company's net loss from continuing operations during that tax year.

No additional provision has been made for U.S. income taxes related to the undistributed earnings of the wholly-owned subsidiaries of Yield10 Bioscience, Inc. or for unrecognized deferred tax liabilities for temporary differences related to investments in subsidiaries as the amounts are not significant. As such, earnings are expected to be permanently reinvested, the investments are essentially permanent in duration, or the Company has concluded that no additional tax liability will arise as a result of the distribution of such earnings. A liability could arise if amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not practical to estimate the additional income taxes related to permanently reinvested earnings or the basis differences related to investment in subsidiaries. Unremitted earnings at December 31, 2017 and December 31, 2016 approximated $482 and $346, respectively. As a result of TCJA, the Company is reviewing its position but does not believe there will be a material impact. The Company will finalize its analysis by the fourth quarter of 2018.

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2017
Compensation and Retirement Disclosure [Abstract]
Employee Benefits	Employee Benefits The Company maintains a 401(k) savings plan in which substantially all of its regular U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the plan, subject to eligibility requirements and annual IRS limitations. The Company's plan provides for a matching contribution in common stock of up to 4.5% of a participant's total compensation dependent upon the level of participant contributions made during the plan year. Pursuant to this plan, the Company issued 22,493, and 31,912 shares of common stock during the years ended December 31, 2017, and 2016, respectively, and recorded $86, and $281, respectively, of related expense. Company contributions are fully vested upon issuance.

U.S. Department of Energy Grants	12 Months Ended
U.S. Department of Energy Grants	Dec. 31, 2017
Research and Development Arrangement with Federal Government [Abstract]
U.S. Department of Energy Grants	U.S. Department of Energy Grants In 2015, the Company entered into a multi-year $1,997 grant agreement entitled, Production of High Oil, Transgene Free Camelina Sativa Plants through Genome Editing, with the U.S. Department of Energy for the development of Camelina sativa feedstock. The Company is using the funds to perform research to increase oil content and/or seed yield to maximize oil yields per acre. Continued receipt of grant proceeds is contingent upon the availability of government appropriated funds and the Company's ability to make substantial progress towards meeting the objectives of the award. The Company recognizes revenue from the grant over the term of the agreement as it incurs related research and development costs and provided it meets its prorated cost-sharing obligation of approximately $500. During the years ended December 31, 2017 and 2016, the Company recognized $913 and $913, respectively, in revenue related to this grant. The grant is expected to complete in June 2018. In 2011, the Company entered into a multi-year $6,000 grant agreement entitled, Renewable Enhanced Feedstocks for Advanced Biofuels and Bioproducts, with the U.S. Department of Energy for the development of switchgrass. The Company used the funds to perform research to enhance the yield of bio-based products, biopower, or fuels made from switchgrass to produce denser biomass and other products that can be further processed to make fuels such as butanol, chemicals such as propylene, and other materials to improve the economic competitiveness of future biorefineries. The Company recognized revenue from the grant over the term of the agreement as it incurred related research and development costs and it met its prorated cost-sharing obligation of approximately $3,900. During the year ended December 31, 2016, the Company recognized the final $1,028 in revenue related to this grant.

Restructuring

12 Months Ended

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring

In July 2016, the Company announced a strategic restructuring under which Yield10 Bioscience became the core business and the biopolymer operations were discontinued. As part of its strategic restructuring, the Company substantially reduced staffing levels, and in January 2017, the Company formally changed its name to Yield10 Bioscience, Inc. See Note 14, Discontinued Operations.

In connection with the wind down of biopolymer operations, the Company ceased pilot production of biopolymer materials and reached agreements with the owner-operators of its biopolymer production facilities regarding the termination of their services. Through December 31, 2017, the Company made cumulative cash payments of $1,956, issued 27,500 shares of company common stock with a fair market value of $85 and transferred certain biopolymer-related production equipment with a net book value of $111 to settle a portion of these agreements and other restructuring activities. Remaining cash restructuring costs at December 31, 2017, of $489 are expected to be paid out at various times through May 2018.



	Biopolymer Production Agreements			Employee Severance and Related Costs			Total
Aggregate Charges and Amounts Accrued	$	2,641		$	872		$	3,513
Paid in Cash	(1,956		)	(872		)	(2,828		)
Paid through Stock and Equipment	(196		)	—			(196		)
Ending Balance Accrued at December 31, 2017	$	489		$	—		$	489

With the exception of approximately $226 of the $872 in employee severance and related costs incurred for non-biopolymer employees, total restructuring costs shown in the table above were classified within discontinued operations in the Company's consolidated statement of operations for the year ended December 31, 2016. Amounts related to the biopolymer production agreements were included in research and development expenses within discontinued operations for the year ended December 31, 2016, as shown in Note 14. Remaining unpaid manufacturing contract termination costs of $489 are included in accrued expenses in the Company's consolidated balance sheet at December 31, 2017.

Discontinued Operation

12 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operation

In July 2016, the Company announced a strategic restructuring plan under which Yield10 Bioscience became its core business. Yield10 Bioscience discontinued its biopolymer operations and eliminated approximately 45 positions in its biopolymer operations and corporate organization.

As part of this strategic shift, the Company completed the sale of its biopolymer intellectual property and certain equipment and inventory to an affiliate of CJ during September 2016. The $10,000 purchase price paid by CJ was primarily for the acquisition of intellectual property, including the Company’s PHA strains, patent rights, know-how and its rights, title and interest in certain license agreements. None of this intellectual property was previously capitalized to the Company’s balance sheet. As such, the transaction resulted in a gain on the sale of approximately $9,868, net of the book value of the equipment sold. In addition to the CJ purchase, other parties acquired various capital equipment of the biopolymer operation for a total purchase price of approximately $428, resulting in a net loss on sale of this equipment of approximately $35.

The Company has not and will not have further involvement in the operations of the discontinued biopolymer business.

The following are the major items comprising income or loss from discontinued operations for the year ended December 31, 2016.



	Year Ended December 31, 2016
Total revenue	$	4,945
Costs and expenses:
Cost of product revenue	793
Research and development	9,854
Selling, general and administrative	1,449
Net gain on sales of biopolymer assets	(9,833		)
Total costs and expenses	2,263
Income from discontinued operations before income tax provision	$	2,682
Income tax provision	(1,097		)
Total net income (loss) from discontinued operations	$	1,585

The following are the non-cash operating items and investing items related to discontinued operations for the year ended December 31, 2016.



	Year Ended December 31, 2016
Non-cash operating items:
Depreciation	$	326
Charge for 401(k) company common stock match	$	118
Stock-based compensation	$	217
Inventory impairment	$	199
Non-cash restructuring expense paid through stock and equipment	$	196
Gain on sale of discontinued operation and property and equipment	$	(9,833	)

Investing item:
Purchases of property and equipment	$	193

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

Geographic Information

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Geographic Information

The geographic distribution of the Company's revenues and long-lived assets from continuing operations is summarized as follows:



	U.S.		Canada		Eliminations			Total
Year Ended December 31, 2017
Net revenues to unaffiliated customers	$	944	$	—	$	—		$	944
Inter-geographic revenues	—		1,154		(1,154		)	—
Net revenues	$	944	$	1,154	$	(1,154	)	$	944
Identifiable long-lived assets	$	1,533	$	6	$	—		$	1,539
Year Ended December 31, 2016
Net revenues to unaffiliated customers	$	1,159	$	—	$	—		$	1,159
Inter-geographic revenues	—		906		(906		)	—
Net revenues	$	1,159	$	906	$	(906	)	$	1,159
Identifiable long-lived assets	$	1,739	$	—	$	—		$	1,739

Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled. During 2017, grant revenue earned from the Company's Camelina grant with the Department of Energy and subaward with North Carolina State University totaled $913 and $30, or 97% and 3%, respectively, of total revenue. During 2016, revenue earned from the Company's Camelina grant and subaward with North Carolina State University totaled $913 and $246, or 79% and 21% of total revenue.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

Investments

Restricted Cash

Foreign Currency Translation

Comprehensive Income (Loss)

Concentration of Credit Risk

The Company's receivables related to government grants are believed to have a low risk of default.

Fair Value Measurements

Segment Information

Property and Equipment



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and Fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

The Company records incentive payments received from its landlords as a lease incentive obligation and amortizes these amounts as reductions to lease expense over the lease term.

Impairment of Long-Lived Assets

Revenue Recognition

Grant Revenue

Research and Development

General, and Administrative Expenses

General and Administrative Expenses

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

Basic and Diluted Net Loss per Share

Income Taxes

Recent Accounting Standards Changes

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of estimated useful life of assets used to compute depreciation using the straight-line method

Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and Fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

Property and equipment consist of the following:



	Year ended December 31,
	2017			2016
Equipment	$	1,059		$	1,048
Furniture and fixtures	119			226
Leasehold improvements	1,749			1,825
Software	96			116
Total property and equipment, at cost	3,023			3,215
Less: Accumulated depreciation	(1,484		)	(1,476		)
Property and equipment, net	$	1,539		$	1,739

Schedule of shares used to calculate diluted earnings per share



	Year Ended December 31,
	2017	2016
Options	622,329	89,862
Restricted stock awards	16,165	70,748
Series A Convertible Preferred Stock	30,553	—
Warrants	943,749	393,300
Total	1,612,796	553,910

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of components of property and equipment

Depreciation is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:



Asset Description		Estimated Useful Life (years)
Equipment		3
Furniture and Fixtures		5
Software		3
Leasehold improvements		Shorter of useful life or term of lease

Property and equipment consist of the following:



	Year ended December 31,
	2017			2016
Equipment	$	1,059		$	1,048
Furniture and fixtures	119			226
Leasehold improvements	1,749			1,825
Software	96			116
Total property and equipment, at cost	3,023			3,215
Less: Accumulated depreciation	(1,484		)	(1,476		)
Property and equipment, net	$	1,539		$	1,739

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:



	Year ended December 31,
	2017		2016
Employee compensation and benefits	$	646	$	713
Commercial manufacturing	489		939
Professional services	335		459
Other	829		591
Total accrued expenses	$	2,299	$	2,702

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of the Company's future minimum payments required under operating leases

At December 31, 2017, the Company's future minimum payments required under operating leases are as follows:



Year ended December 31,	Minimum lease payment
2018	$	917
2019	855
2020	734
2021	654
2022	676
2023 and thereafter	2,832
Total	$	6,668

Capital Stock (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2017:



Issuance	Number of Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
June 2015 Private Placement	393,300	$	39.80	June 15, 2019
July 2017 Registered Direct Offering	570,784	$	5.04	January 7, 2024
December 2017 Public Offering - Series A	6,439,000	$	2.25	December 21, 2022
December 2017 Public Offering - Series B	3,219,502	$	2.25	September 21, 2018
Consultant	30,000	$	2.90	September 11, 2024
Total	10,652,586

Schedule of Stock by Class



	December 31, 2017	December 31, 2016
Stock Options	702,033	605,077
RSUs	14,367	21,735
Series A Convertible Preferred Stock	811,555	—
Warrants	10,652,586	393,300
Total number of common shares reserved for future issuance	12,180,541	1,020,112

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

+ Details

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of the activity related to the shares of common stock covered by outstanding options under the plans

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:



	Number of Shares		Weighted Average Exercise Price	Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2016	605,077		$34.49
Granted	122,998		2.75
Exercised	—		—
Forfeited	(2,534	)	5.55
Expired	(23,508	)	417.30
Balance at December 31, 2017	702,033		16.21	8.40	$—
Vested and expected to vest at December 31, 2017	702,033		16.21	8.38	—
Exercisable at December 31, 2017	436,522		22.87	8.12	—

Schedule of assumptions used in determining fair value of stock options granted using the Black-Scholes option pricing model



	Year Ended December 31,
	2017	2016
Expected dividend yield	—	—
Risk-free rate	1.79% - 2.20%	1.24% - 2.04%
Expected option term (in years)	5.3-5.5	5.4-5.7
Volatility	97% - 104%	93% - 96%

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of RSU activity for the year ended December 31, 2017 is as follows:



	Number of RSUs			Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2016	21,735
Awarded	25,337
Released	(32,542		)
Forfeited	(163		)
Outstanding at December 31, 2017	14,367			0.75

Weighted average remaining recognition period (years)	1.25
Weighted average grant date fair value of RSUs granted during the year ended December 31, 2017	$	4.63

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of components of profit (loss) before provision for income taxes

The components of loss from continuing operations before provision for income taxes consist of the following:



	Year Ended December 31,
	2017			2016
Domestic	$	(9,523	)	$	(10,318	)
Foreign	126			48
Loss before taxes	$	(9,397	)	$	(10,270	)

Schedule of significant components of the Company's net deferred tax asset

Significant components of the Company's net deferred tax assets are as follows:



	Year Ended December 31,
	2017			2016
Deferred Tax Assets:
Net operating loss carryforward	$	20,490		$	25,182
Capitalization of research and development expense	1,606			2,634
Credit carryforwards	2,493			2,048
Depreciation	990			1,505
Stock compensation	1,035			2,414
Other temporary differences	794			1,202
Total deferred tax assets.	27,408			34,985
Valuation allowance	(27,408		)	(34,985		)
Net deferred tax assets	—			—
Deferred Tax Liabilities:
Other temporary differences	—			—
Net deferred taxes	$	—		$	—

Schedule of items accounting for the difference between the income tax benefit computed at the federal statutory rate and the provision for income taxes

The items accounting for the difference between the income tax benefit computed at the federal statutory rate of 34% and the provision for income taxes were as follows:



	Year Ended December 31,
	2017		2016
Federal income tax at statutory federal rate	34.0	%	34.0	%
State taxes	4.9	%	5.0	%
Permanent differences	(2.3	)%	(1.9	)%
Tax credits	3.7	%	7.4	%
Federal rate change under tax reform	(112.9	)%	0.0	%
State rate change on deferred balances	0.1	%	(0.6	)%
Impact of ownership change	0.0	%	(6.1	)%
Stock compensation	(12.7	)%	(22.9	)%
Other	1.2	%	(0.5	)%
Change in valuation allowance	84.0	%	(3.7	)%
Total	0.0	%	10.7	%

Restructuring (Tables)

12 Months Ended

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs



	Biopolymer Production Agreements			Employee Severance and Related Costs			Total
Aggregate Charges and Amounts Accrued	$	2,641		$	872		$	3,513
Paid in Cash	(1,956		)	(872		)	(2,828		)
Paid through Stock and Equipment	(196		)	—			(196		)
Ending Balance Accrued at December 31, 2017	$	489		$	—		$	489

Discontinued Operation (Tables)

12 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of discontinued operations

The following are the major items comprising income or loss from discontinued operations for the year ended December 31, 2016.



	Year Ended December 31, 2016
Total revenue	$	4,945
Costs and expenses:
Cost of product revenue	793
Research and development	9,854
Selling, general and administrative	1,449
Net gain on sales of biopolymer assets	(9,833		)
Total costs and expenses	2,263
Income from discontinued operations before income tax provision	$	2,682
Income tax provision	(1,097		)
Total net income (loss) from discontinued operations	$	1,585

The following are the non-cash operating items and investing items related to discontinued operations for the year ended December 31, 2016.



	Year Ended December 31, 2016
Non-cash operating items:
Depreciation	$	326
Charge for 401(k) company common stock match	$	118
Stock-based compensation	$	217
Inventory impairment	$	199
Non-cash restructuring expense paid through stock and equipment	$	196
Gain on sale of discontinued operation and property and equipment	$	(9,833	)

Investing item:
Purchases of property and equipment	$	193

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Geographic Information (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Schedule of the geographic distribution of revenues and long-lived assets from continuing operations

The geographic distribution of the Company's revenues and long-lived assets from continuing operations is summarized as follows:



	U.S.		Canada		Eliminations			Total
Year Ended December 31, 2017
Net revenues to unaffiliated customers	$	944	$	—	$	—		$	944
Inter-geographic revenues	—		1,154		(1,154		)	—
Net revenues	$	944	$	1,154	$	(1,154	)	$	944
Identifiable long-lived assets	$	1,533	$	6	$	—		$	1,539
Year Ended December 31, 2016
Net revenues to unaffiliated customers	$	1,159	$	—	$	—		$	1,159
Inter-geographic revenues	—		906		(906		)	—
Net revenues	$	1,159	$	906	$	(906	)	$	1,159
Identifiable long-lived assets	$	1,739	$	—	$	—		$	1,739

Nature of Business and Basis of Presentation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) employee	Dec. 31, 2016 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2015 USD ($)
Related party transactions
Deferred revenues recognized			$ 38,885
Restructuring target number of employees remaining \| employee	20
Restructuring charges		$ 3,513
Unrestricted cash and cash equivalents	$ 14,487	7,309		$ 12,269
Period over which company's present capital resources are not sufficient to fund its planned operations	12 months
Discontinued operations
Related party transactions
Restructuring costs remaining	$ 489	$ 3,513

Summary of Significant Accounting Policies (Details)		12 Months Ended
Summary of Significant Accounting Policies (Details)	May 26, 2017	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Oct. 31, 2015 USD ($)
Concentration of credit risk
Shares issued for each share converted	10
Restricted cash		$ 317,000	$ 432,000
Deferred equity financing costs		0	622,000
Unbilled receivables, current		119,000
Unrecognized tax benefits		0
Government grants
Concentration of credit risk
Unbilled receivables, current		$ 104,000	$ 187,000
Receivables/sales (as a percent)		87.00%
Aspire
Concentration of credit risk
Common stock, commitment to sell, amount				$ 20,000,000	$ 20,000,000

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
Summary of Significant Accounting Policies (Details 2)	Dec. 31, 2017 segment
Segment Information
Number of operating segments	1
Equipment
Property and Equipment
Estimated Useful Life	3 years
Furniture and fixtures
Property and Equipment
Estimated Useful Life	5 years
Software
Property and Equipment
Estimated Useful Life	3 years

Summary of Significant Accounting Policies (Details 3) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	1,612,796	553,910
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	622,329	89,862
Restricted stock awards
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	16,165	70,748
Series A Convertible Preferred Stock
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	30,553	0
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	943,749	393,300

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Assets, fair value	$ 11,025	$ 1,018

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property and equipment, net
Total property and equipment, at cost	$ 3,023	$ 3,215
Less: Accumulated depreciation	(1,484)	(1,476)
Property and equipment, net	1,539	1,739
Depreciation expense for continuing operations	206	177
Equipment
Property and equipment, net
Total property and equipment, at cost	1,059	1,048
Furniture and fixtures
Property and equipment, net
Total property and equipment, at cost	119	226
Leasehold improvements
Property and equipment, net
Total property and equipment, at cost	1,749	1,825
Software
Property and equipment, net
Total property and equipment, at cost	$ 96	$ 116

Accrued Expenses (Details) - USD ($) $ in Thousands	1 Months Ended
Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Professional Fees	$ 216
Employee compensation and benefits	646	$ 713
Commercial manufacturing	489	939
Professional services	335	459
Other	829	591
Total accrued expenses	$ 2,299	2,702
Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		$ 626

Commitments and Contingencies - Details Textual (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) ft²	Oct. 31, 2016 USD ($) ft²	Jan. 20, 2016 ft²
Operating Leased Assets [Line Items]
Operating leases, rent expense, net	$ 954	$ 1,889
Area of real estate property \| ft²		29,622
Security deposit		$ 0
Receivable, leasehold Improvements	1
Operating leases, landlord reimbursement for lease improvements, additional payments	0
Restructuring contract termination fees payable	$ 489
Subsidiary
Operating Leased Assets [Line Items]
Area of real estate property \| ft²				4,095
650 Suffolk Street, Lowell, Massachusetts
Operating Leased Assets [Line Items]
Area of real estate property \| ft²				13,702
Lease renewal term	5 years
CJ Cheil Jedang Corporation
Operating Leased Assets [Line Items]
Area of real estate property \| ft²			9,874
Security deposit			$ 103
Future minimum payments due	$ 6,668

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Future minimum lease payments
2017	$ 917
2018	855
2019	734
2020	654
2021	676
2023 and thereafter	$ 2,832

License Agreements and Related Parties (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Jun. 30, 2016 USD ($)	May 31, 2016 USD ($) production_strain	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Related party transactions
License and royalty revenue	$ 1,000		$ 850
Outstanding receivable			0	$ 1
Revenue, Product Sales To Related Party			150
Tepha, Inc.
Related party transactions
Related party prepayment		$ 2,000
Number of prepaid additional production strains \| production_strain		2
License and royalty revenue			2,272
Related Party Transaction, Purchases from Related Party			11
Outstanding receivable			$ 1

Capital Stock (Details)				1 Months Ended			2 Months Ended	3 Months Ended	12 Months Ended
Capital Stock (Details)	Dec. 31, 2017 $ / shares shares	Jul. 07, 2017 USD ($) $ / shares shares	May 26, 2017 shares	Dec. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2016 shares	Oct. 31, 2015 USD ($)	Mar. 05, 2018 shares	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 27, 2017 shares	Sep. 12, 2017 $ / shares shares	Dec. 31, 2015 USD ($)
Class of Stock [Line Items]
Common stock, shares authorized (in shares)	40,000,000		250,000,000	40,000,000					40,000,000	250,000,000	40,000,000
Proceeds from public stock offerings, net of issuance costs \| $		$ 1,966,000							$ 13,318,000	$ 0
Issuance costs from private placement \| $		$ 317,000		$ 1,171,000
Issuance of stock in connection with private placement (in shares)		570,784			27,500
Share price (in USD per share) \| $ / shares		$ 4.00
Investment warrants, exercise price (in USD per share) \| $ / shares		$ 5.04
Expected volatility rate									125.00%
Deemed dividend on Series A Convertible Preferred Stock issuance \| $									$ 1,427,000	0
Net loss \| $									(9,396,000)	(7,604,000)
Net loss applicable to common shareholders \| $									(10,823,000)	$ (7,604,000)
Shares issued for each share converted			10
Stock issued during period, shares, reverse stock splits			28,700,000
Stock issued during period, shares, stock splits			2,900,000
Write off of deferred debt issuance cost \| $									$ 622,000
Preferred stock, shares authorized	5,000,000			5,000,000					5,000,000	5,000,000
Preferred stock, par value per share (in dollars per share) \| $ / shares	$ 0.01			$ 0.01					$ 0.01	$ 0.01
Preferred stock, shares outstanding	1,826			1,826					1,826	0
Aspire
Class of Stock [Line Items]
Common stock, commitment to sell, amount \| $						$ 20,000,000							$ 20,000,000
Long-term purchase commitment, period						30 months
Common Stock
Class of Stock [Line Items]
Issuance of stock in connection with private placement (in shares)									4,667,000
Issuance of common stock upon conversion of preferred stock (in shares)									960,445	27,500
Common Stock \| Aspire
Class of Stock [Line Items]
Issuance of stock in connection with private placement (in shares)									570,784
Series A Warrant
Class of Stock [Line Items]
Fair Value Assumptions, Expected Term				5 years
Risk free interest rate									2.20%
Series B Warrant
Class of Stock [Line Items]
Fair Value Assumptions, Expected Term				9 months
Risk free interest rate									1.70%
Consultant Offering
Class of Stock [Line Items]
Number of securities called by warrants (in shares)												30,000
Affiliated Entity
Class of Stock [Line Items]
Exercise price of warrants (in USD per share) \| $ / shares												$ 2.90
Class A Units
Class of Stock [Line Items]
Issuance of stock in connection with private placement (in shares)				4,667,000
Share price (in USD per share) \| $ / shares	$ 2.25			$ 2.25					$ 2.25
Class A Units \| Series A Warrant
Class of Stock [Line Items]
Class of warrant or right expiration term				5 years
Exercise price of warrants (in USD per share) \| $ / shares	$ 2.25			$ 2.25					$ 2.25
Number of securities called by each warrant or right	1			1					1
Class A Units \| Series B Warrant
Class of Stock [Line Items]
Class of warrant or right expiration term				9 months
Exercise price of warrants (in USD per share) \| $ / shares	$ 2.25			$ 2.25					$ 2.25
Number of securities called by each warrant or right	0.5			0.5					0.5
Class B Units
Class of Stock [Line Items]
Issuance of stock in connection with private placement (in shares)				3,987
Share price (in USD per share) \| $ / shares	$ 1,000			$ 1,000					$ 1,000
Preferred Stock Conversions, Conversion Price \| $ / shares	$ 2.25			$ 2.25					$ 2.25
Class B Units \| Series A Warrant
Class of Stock [Line Items]
Class of warrant or right expiration term				5 years
Number of securities called by warrants (in shares)	445			445					445
Investment warrants, exercise price (in USD per share) \| $ / shares				$ 2.25
Class B Units \| Series B Warrant
Class of Stock [Line Items]
Class of warrant or right expiration term				9 months
Number of securities called by warrants (in shares)	223			223					223
Investment warrants, exercise price (in USD per share) \| $ / shares				$ 2.25
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Conversion of stock, shares converted (in shares)	(2,161)
Preferred stock, redemption conditions, minimum market price per share (in USD per share) \| $ / shares									$ 6.75
Preferred stock, redemption conditions, minimum daily market trading volume \| $									$ 175,000
Preferred stock, shares outstanding	1,826			1,826					1,826
Scenario, Forecast
Class of Stock [Line Items]
Issuance costs from private placement \| $								$ 221,000
Subsequent Event \| Common Stock
Class of Stock [Line Items]
Issuance of common stock upon conversion of preferred stock (in shares)							763,556
Subsequent Event \| Series A Convertible Preferred Stock
Class of Stock [Line Items]
Conversion of stock, shares converted (in shares)							1,718

Capital Stock - Schedule Of Warrants Issuance (Details) - $ / shares	Dec. 31, 2017	Jul. 31, 2017	Jun. 30, 2015
Consultant
Class of Stock [Line Items]
Number of securities called by warrants (in shares)	30,000
Exercise price of warrants (in USD per share)	$ 2.90
Class B Units
Class of Stock [Line Items]
Number of securities called by warrants (in shares)	3,219,502
Exercise price of warrants (in USD per share)	$ 2.25
Class A Units
Class of Stock [Line Items]
Number of securities called by warrants (in shares)	6,439,000
Exercise price of warrants (in USD per share)	$ 2.25
Warrants
Class of Stock [Line Items]
Number of securities called by warrants (in shares)		570,784	393,300
Exercise price of warrants (in USD per share)		$ 5.04	$ 39.80

Capital Stock - Schedule of Common Stock Reserved For Future Issuance (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	12,180,541	1,020,112
Options
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	702,033	605,077
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	14,367	21,735
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	811,555	0
Warrants
Class of Stock [Line Items]
Number of securities called by warrants (in shares)	10,652,586	393,300

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended			144 Months Ended
	Oct. 26, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Stock-based compensation
Stock-based compensation		$ 1,395	$ 848
Awarded		25,337
Aggregate Intrinsic Value
Balance at December 31, 2015		$ 0			$ 0
Vested and expected to vest at December 31, 2015		0			0
Exercisable at December 31, 2015		$ 0			$ 0
Stock options
Stock-based compensation
Vesting period for options granted	2 years
Expiration period		10 years
Number of Shares
Balance at the beginning of the period (in shares)		605,077
Granted (in shares)	456,000	122,998
Exercised (in shares)		0	0
Forfeited (in shares)		(2,534)
Expired (in shares)		(23,508)
Balance at the end of the period (in shares)		702,033	605,077		702,033
Vested and expected to vest at the end of the period (in shares)		702,033			702,033
Options exercisable at the end of the period (in shares)		436,522			436,522
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)		$ 34.49
Granted (in dollars per share)		2.75
Exercised (in dollars per share)		0.00
Forfeited (in dollars per share)		5.55
Expired (in dollars per share)		417.30
Balance at the end of the period (in dollars per share)		16.21	$ 34.49		$ 16.21
Vested and expected to vest at the end of the period (in dollars per share)		16.21			16.21
Options exercisable at the end of the period (in dollars per share)		$ 22.87			$ 22.87
Remaining Contractual Term
Weighted average remaining contractual term		8 years 4 months 24 days
Vested and expected to vest at the end of the period		8 years 4 months 17 days
Options exercisable at the end of the period		8 years 1 month 13 days
Additional disclosures
Weighted average grant date fair value of options granted (in dollars per share)		$ 2.10	$ 3.06
Stock options \| Minimum
Stock-based compensation
Vesting period for options granted		1 year
Stock options \| Maximum
Stock-based compensation
Vesting period for options granted		4 years
Stock options \| 2006 Plan
Stock-based compensation
Further grants or awards after termination of plan (in shares)		0
Number of Shares
Granted (in shares)					146,724
Stock options \| 2014 Plan
Stock-based compensation
Options awarded		663,104			663,104
Number of Shares
Balance at the end of the period (in shares)		657,882			657,882
Restricted stock awards \| 2014 Plan
Stock-based compensation
Options awarded		144,541			144,541
Number of Shares
Balance at the end of the period (in shares)		14,367			14,367
Restricted Stock Units (RSUs) \| Joseph Shaulson
Stock-based compensation
Awarded		25,337		8,125

Stock-Based Compensation (Details 2) - USD ($) $ in Thousands		12 Months Ended
	Oct. 26, 2016	Dec. 31, 2017	Dec. 31, 2016
Stock-based compensation
Weighted average period over which unrecognized compensation expense is expected to be recognized		1 year 3 months
Stock options
Assumptions used to determine fair value of stock options
Vesting period for options granted	2 years
Stock options \| Employee and Director
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized		$ 986
Weighted average period over which unrecognized compensation expense is expected to be recognized		9 months 22 days
Assumptions used to determine fair value of stock options
Expected dividend yield (as a percent)		0.00%	0.00%
Risk-free rate, minimum (as a percent)		1.79%	1.24%
Risk-free rate, maximum (as a percent)		2.20%	2.04%
Volatility, minimum (as a percent)		97.00%	93.00%
Volatility, maximum (as a percent)		104.00%	96.00%
Stock options \| Minimum
Assumptions used to determine fair value of stock options
Vesting period for options granted		1 year
Stock options \| Minimum \| Employee and Director
Assumptions used to determine fair value of stock options
Expected option term (in years)		5 years 3 months 18 days	5 years 4 months 24 days
Stock options \| Maximum
Assumptions used to determine fair value of stock options
Vesting period for options granted		4 years
Stock options \| Maximum \| Employee and Director
Assumptions used to determine fair value of stock options
Expected option term (in years)		5 years 6 months	5 years 8 months 12 days
Vesting in year one` \| Nonemployee Stock Options
Assumptions used to determine fair value of stock options
Award vesting rights		50.00%
Vesting in first six months \| Stock options
Assumptions used to determine fair value of stock options
Award vesting rights		25.00%
Vesting in second six months \| Stock options
Assumptions used to determine fair value of stock options
Award vesting rights		25.00%
Vesting in year two \| Nonemployee Stock Options
Assumptions used to determine fair value of stock options
Award vesting rights		50.00%

Stock-Based Compensation - Stock Options (Details) $ in Thousands			1 Months Ended	12 Months Ended		144 Months Ended
	Nov. 04, 2016 shares	Oct. 26, 2016 installment shares	Dec. 31, 2013 shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2017 shares
Stock options
Stock-based compensation
Vesting period for options granted		2 years
Expiration period				10 years
Granted (in shares)		456,000		122,998
Number of periodic vesting installments \| installment		4
Award expiration period		10 years
Exercise of common stock options (in shares)				0	0
Weighted average remaining contractual term				8 years 4 months 24 days
Stock options \| Vesting in first six months
Stock-based compensation
Award vesting rights				25.00%
Award vesting rights		0.25
Stock options \| Vesting in second six months
Stock-based compensation
Award vesting rights				25.00%
Stock options \| Vesting in third six months
Stock-based compensation
Award vesting rights				25.00%
Stock options \| Vesting in fourth six months
Stock-based compensation
Award vesting rights				25.00%
Restricted Stock Units (RSUs)
Stock-based compensation
Taxes paid on employees' behalf related to vesting of stock awards \| $				$ (12)	$ (296)
Chief Executive Officer \| Stock options
Stock-based compensation
Granted (in shares)	75,000		19,167
Options vested (in shares)	14,375
Chief Executive Officer \| Stock options \| Vesting upon execution of agreement
Stock-based compensation
Award vesting rights				100.00%
Chief Executive Officer \| Restricted Stock Units (RSUs)
Stock-based compensation
Accelerated vesting (in shares)	15,125
Minimum \| Stock options
Stock-based compensation
Vesting period for options granted				1 year
Maximum \| Stock options
Stock-based compensation
Vesting period for options granted				4 years
2006 Plan \| Stock options
Stock-based compensation
Granted (in shares)						146,724
Number of options nonvested (in shares)				24,984		24,984

Stock-Based Compensation RSU (Details)	12 Months Ended
Stock-Based Compensation RSU (Details)	Dec. 31, 2017 $ / shares shares	Dec. 31, 2015 shares
Number of RSUs
Outstanding at December 31, 2016	21,735
Awarded	25,337
Released	(32,542)
Forfeited	(163)
Outstanding at December 31, 2017	14,367
Weighted average remaining recognition period (years)	1 year 3 months
Weighted average grant date fair value of RSUs granted during the year ended December 31, 2017 \| $ / shares	$ 4.63
Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2017	9 months
Director \| Restricted Stock Units (RSUs)
Number of RSUs
Awarded	25,337	8,125
Management \| Restricted Stock Units (RSUs)
Number of RSUs
Awarded		20,397
Management \| Long-Term Incentive RSU
Number of RSUs
Awarded		90,682
Number of periodic vesting installments		4

Stock-Based Compensation - Expense Information for Non-employee Stock Awards (Details) - Nonemployee Stock Options - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock-based compensation
Stock options authorized		5,500
Award vesting rights	0.5
Period for recognition of compensation expense	2 years
Granted (in shares)	0

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Components of profit (loss) before provision for income taxes
Domestic	$ (9,523)	$ (10,318)
Foreign	126	48
Loss before taxes	(9,397)	(10,270)
Deferred Tax Assets:
Net operating loss carryforward	20,490	25,182
Capitalization of research and development expense	1,606	2,634
Credit carryforwards	2,493	2,048
Depreciation	990	1,505
Stock compensation	1,035	2,414
Other temporary differences	794	1,202
Total deferred tax assets.	27,408	34,985
Valuation allowance	(27,408)	(34,985)
Net deferred tax assets	0	0
Deferred Tax Liabilities:
Other temporary differences	0	0
Net deferred taxes	$ 0	$ 0
Difference between income tax benefit computed at the federal statutory rate and the provision for income taxes
Federal income tax at statutory federal rate	34.00%	34.00%
State taxes	4.90%	5.00%
Permanent differences	(2.30%)	(1.90%)
Tax credits	3.70%	7.40%
Federal rate change under tax reform	(112.90%)	(0.00%)
State rate change on deferred balances	0.10%	(0.60%)
Impact of ownership change	0.00%	(6.10%)
Stock compensation	(12.70%)	(22.90%)
Other	1.20%	(0.50%)
Change in valuation allowance	84.00%	(3.70%)
Total	0.00%	10.70%

Income Taxes - Details Textual (Details) - USD ($)	1 Months Ended	12 Months Ended
Income Taxes - Details Textual (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Contingency [Line Items]
Revaluation provision for income tax expense	$ 10,609,000
Income tax penalties and interest accrued	0	$ 0	$ 0	$ 0
Income tax provision for discontinued operations		0	1,097,000
Income tax expense (benefit)		0	(1,097,000)
Provision for income taxes for undistributed earnings of foreign subsidiaries	0
Undistributed earnings of foreign subsidiaries	482,000	482,000	$ 346,000
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Operating loss carryforwards	72,941,000	72,941,000
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Operating loss carryforwards	68,028,000	68,028,000
Foreign Tax Authority
Income Tax Contingency [Line Items]
Operating loss carryforwards	2,702,000	2,702,000
Research Tax Credit Carryforward \| Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	1,282,000	1,282,000
Research Tax Credit Carryforward \| State and Local Jurisdiction
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	$ 787,000	$ 787,000

Employee Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
Employee Benefits (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Maximum contribution by participants under the 401(k) savings plan (as a percent)	60.00%
Employer's matching contribution in common stock as a percentage of a participant's total compensation, percent	4.50%
Common stock issued under the 401(k) savings plan (in shares)	22,493	31,912
Related expense for common stock issued under the 401(k) savings plan	$ 86	$ 281

U.S. Department of Energy Grants (Details) - USD ($)	12 Months Ended
U.S. Department of Energy Grants (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2011
Production of High Oil, Transgene Free Camelina Sativa Plants through Genome Editing
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Multi-year grant agreement amount			$ 1,997,000
Prorated cost-sharing obligation amount	$ 500,000
Revenue recognized related to the multi-year grant agreement	$ 913,000	$ 913,000
Renewable Enhanced Feedstock for Advanced Biofuels and Bioproducts
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Multi-year grant agreement amount				$ 6,000,000
Prorated cost-sharing obligation amount				$ 3,900,000
Revenue recognized related to the multi-year grant agreement		$ 1,028,000

Restructuring - Textual Details (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Jul. 07, 2017	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Issuance of stock in connection with private placement (in shares)	570,784	27,500
Issuance of stock in connection with private placement, net of offering costs			$ 13,097
Transfer of equipment to settle contractual liability			0	$ 111
Commercial manufacturing			$ 489	939
Biopolymer Production Agreements
Restructuring Cost and Reserve [Line Items]
Issuance of stock in connection with private placement (in shares)			27,500
Issuance of stock in connection with private placement, net of offering costs			$ 85
Transfer of equipment to settle contractual liability			111
Commercial manufacturing			489
Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring reserve				626
Continuing Operations \| Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, current				226
Discontinued operations
Restructuring Cost and Reserve [Line Items]
Payments for restructuring			2,828
Restructuring reserve			489	3,513
Discontinued operations \| Employee severance
Restructuring Cost and Reserve [Line Items]
Payments for restructuring			872
Restructuring reserve			$ 0	$ 872

Restructuring (Details) - USD ($) $ in Thousands	12 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 3,513
Restructuring Reserve [Roll Forward]
Paid through Stock and Equipment	$ 0	(196)
Employee Severance and Related Costs
Restructuring Reserve [Roll Forward]
Aggregate Charges and Amounts Accrued	626
Ending Balance Accrued at December 31, 2017		626
Discontinued operations
Restructuring Reserve [Roll Forward]
Aggregate Charges and Amounts Accrued	3,513
Paid in Cash	(2,828)
Paid through Stock and Equipment	(196)
Ending Balance Accrued at December 31, 2017	489	3,513
Discontinued operations \| Biopolymer Production Agreements
Restructuring Reserve [Roll Forward]
Aggregate Charges and Amounts Accrued	2,641
Paid in Cash	(1,956)
Paid through Stock and Equipment	(196)
Ending Balance Accrued at December 31, 2017	489	2,641
Discontinued operations \| Employee Severance and Related Costs
Restructuring Reserve [Roll Forward]
Aggregate Charges and Amounts Accrued	872
Paid in Cash	(872)
Paid through Stock and Equipment	0
Ending Balance Accrued at December 31, 2017	$ 0	$ 872

Discontinued Operation - Narrative (Details) $ in Thousands	1 Months Ended		12 Months Ended
Discontinued Operation - Narrative (Details) $ in Thousands	Sep. 30, 2016 USD ($)	Jul. 31, 2016 position	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of positions eliminated \| position		45
Proceeds from sale of discontinued operation and property and equipment			$ 0	$ 10,317
CJ Cheil Jedang Corporation
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of discontinued operation and property and equipment	$ 10,000
Net gain on sales of biopolymer assets	9,868
Other Parties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of discontinued operation and property and equipment	428
Net gain on sales of biopolymer assets	$ 35

Discontinued Operation (Details) - USD ($) $ in Thousands	12 Months Ended
Discontinued Operation (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Costs and expenses:
Income tax provision	$ 0	$ (1,097)
Total net income from discontinued operations	$ 0	1,585
Metabolix GmbH
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue		4,945
Costs and expenses:
Cost of product revenue		793
Research and development		9,854
Selling, general and administrative		1,449
Net gain on sales of biopolymer assets		(9,833)
Total costs and expenses		2,263
Income from discontinued operations before income tax provision		2,682
Income tax provision		(1,097)
Total net income from discontinued operations		$ 1,585

Discontinued Operation - Non-cash Operating (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 206	$ 515
Expense for 401(k) company common stock match	85	281
Stock-based compensation	1,395	848
Inventory impairment	0	199
Investing item:
Purchases of property and equipment	$ 6	752
Metabolix GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation		326
Expense for 401(k) company common stock match		118
Stock-based compensation		217
Inventory impairment		199
Non-cash restructuring expense paid through stock and equipment		196
Gain on sale of discontinued operation and property and equipment		(9,833)
Investing item:
Purchases of property and equipment		$ 193

Geographic Information (Details) - USD ($) $ in Thousands	12 Months Ended
Geographic Information (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Geographic Information
Net revenues to unaffiliated customers	$ 944	$ 1,159
Revenues	944	1,159
Identifiable long-lived assets	1,539	1,739
U.S.
Geographic Information
Net revenues to unaffiliated customers	944	1,159
Revenues	944	1,159
Identifiable long-lived assets	1,533	1,739
Canada
Geographic Information
Net revenues to unaffiliated customers	0	0
Revenues	1,154	906
Identifiable long-lived assets	6	0
Eliminations
Geographic Information
Revenues	(1,154)	(906)
Inter-geographic revenues \| Canada
Geographic Information
Revenues	1,154	906
Inter-geographic revenues \| Eliminations
Geographic Information
Revenues	$ (1,154)	$ (906)

Geographic Information (Details 2) - USD ($) $ in Thousands	12 Months Ended
Geographic Information (Details 2) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Revenue earned
Revenue earned from grant	$ 944	$ 1,159
North Carolina State University
Revenue earned
Revenue earned from grant	30
U.S. Department of Energy
Revenue earned
Revenue earned from grant	$ 913
Revenues \| North Carolina State University
Revenue earned
Percentage of total revenue	3.00%
Revenues \| U.S. Department of Energy
Revenue earned
Percentage of total revenue	97.00%
Sales \| North Carolina State University
Revenue earned
Revenue earned from grant		$ 246
Percentage of total revenue		21.22519%
Sales \| U.S. Department of Energy
Revenue earned
Revenue earned from grant		$ 913
Percentage of total revenue		78.77481%